SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Kirk's Market Thoughts
COHR 170.45-2.6%Dec 17 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Kirk © who wrote (11393)6/10/2021 3:48:18 PM
From: Sun Tzu  Read Replies (1) of 26784
 
The most logical and straightforward way of calculating the costs is to simply divide all manufacturing costs (SG&A) by the number of units produced. Anything else would probably be spelled out.

There is a benefit to Pfizer in spreading the SG&A over a larger unit count as the incremental production costs is minimal. This improves Pfizer's profit margins on the vaccines that they do sell.

As to the opportunity costs, I am not an expert in this area, but I'd be very surprised if vaccine production takes away from drug production. I think they are very different processes and use different facilities.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News